NEW YORK (GenomeWeb) – Synthetic biology firm Gen9 has raised $25 million in a private financing round, its president and CEO confirmed to GenomeWeb Daily News.

The company disclosed the financing in a document filed with the US Securities and Exchange Commission last week. Gen9 President and CEO Kevin Munelly told GWDN in an email today that proceeds from the financing will be used to "expand our team and advance additional products and services that will further accelerate the design-build-test cycle for our customers."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Sciencethis week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.